We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.
On January 9, UBS upgraded Oscar Health, Inc. (NYSE:OSCR) to Neutral from Sell and raised its price target to $17 from $12. The firm cited better-than-expected exchange enrollment trends despite the expiration of enhanced subsidies and noted that the shares appear fairly valued at current levels.
In the third quarter of 2025, Oscar Health, Inc. (NYSE:OSCR) reported a 23% year-over-year increase in total revenue to approximately $3.0 billion. Medical loss ratio increased by 380 basis points to 88.5%, reflecting cost pressures during the period. The company also outlined plans to expand into 20 states for 2026, including new entries into Alabama and Mississippi, while launching additional products such as HelloMeno. Management highlighted ongoing investments in technology, including the integration of AI tools through its Oswell platform, aimed at improving operational efficiency and member engagement.
Oscar Health, Inc. (NYSE:OSCR) was founded in 2012 as a technology-focused health insurance company. The company seeks to improve access and affordability through digital tools, virtual care, and data-driven plan design.
While we acknowledge the potential of OSCR as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy
Disclosure: None.
